Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Dragana Milojkovic, MBBS, PhD, Richard E. Clark, Jennifer L Byrne, Brian J.P Huntly, Manoj Raghavan, Farooq A Wandroo, Sahra Ali, Belinda Austen, Jacqueline Ryan, Karsten Friedrich, Nicholas C.P. Cross, PhD, Adam J Mead, MD PhD

Blood (2017) 130 (Supplement 1): 2892.

https://doi.org/10.1182/blood.V130.Suppl_1.2892.2892

Published: 2017

Journal Articles

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Blood (2017) 130 (Supplement 1): 2916.

https://doi.org/10.1182/blood.V130.Suppl_1.2916.2916

Published: 2017

Journal Articles

Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience

Martin C. Müller, MD, Christian Dietz, PhD, Giuseppe Saglio, MD PhD, Francois-Xavier Mahon, MD PhD, Fabrizio Pane, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD

Blood (2017) 130 (Supplement 1): 2874.

https://doi.org/10.1182/blood.V130.Suppl_1.2874.2874

Published: 2017

Journal Articles

Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors

Mohamad Jawhar, MD, Juliana Schwaab, MD, Manja Meggendorfer, PhD, Nicole Naumann, Hans-Peter Horny, MD, Karl Sotlar, MD, Torsten Haferlach, MD, Karla Schmitt, MD, Alice Fabarius, PhD, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD, Andreas Reiter, MD

Blood (2016) 128 (22): 3109.

https://doi.org/10.1182/blood.V128.22.3109.3109

Published: 2016

Journal Articles

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Andreas Reiter, MD, Gunay Ahmadova, MD, Mohamad Jawhar, MD, Andres Virchis, MD, Tim Somervaille, MDPhD, Mark Williams, MD, Bernd Schönberger, MD, Rebecca Frewin, FRCPath, MRCP, MBBS, BSc, Philipp J. Jost, MD, Annett Maschke, MD, Peter Keller, MD, Torsten Haferlach, MD, Nicole Naumann, Juliana Schwaab, MD, Alice Fabarius, PhD, Wolf-Karsten Hofmann, MD, Claudia Haferlach, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD

Blood (2016) 128 (22): 3114.

https://doi.org/10.1182/blood.V128.22.3114.3114

Published: 2016

Journal Articles

The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis

Richard T. Silver, Ariella Barel, Elena Lascu, BA,MA, Ellen K. Ritchie, MD, Gail J. Roboz, MD, Paul Christos, Attilio Orazi, MD, Duane C Hassane, PhD, Wayne Tam, MD PhD, Nicholas C.P. Cross, PhD

Blood (2016) 128 (22): 944.

https://doi.org/10.1182/blood.V128.22.944.944

Published: 2016

Journal Articles

Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis

Mohamad Jawhar, MD, Juliana Schwaab, MD, Nicole Naumann, Sebastian Kluger, Hans-Peter Horny, MD, Karl Sotlar, MD, Torsten Haferlach, MD, Georgia Metzgeroth, MD, Alice Fabarius, PhD, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Manja Meggendorfer, PhD, Andreas Reiter, MD

Blood (2016) 128 (22): 945.

https://doi.org/10.1182/blood.V128.22.945.945

Published: 2016

Journal Articles

Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis

Nicole Naumann, Mohamad Jawhar, MD, Juliana Schwaab, MD, Georgia Metzgeroth, MD, Henning D Popp, MD, Nada Khaled, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Peter Valent, MD, Claudia Haferlach, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, Prof, MD, Manja Meggendorfer, PhD, Nicholas C.P. Cross, PhD, Wolf-Karsten Hofmann, MD, Andreas Reiter, MD, Alice Fabarius, PhD

Blood (2016) 128 (22): 947.

https://doi.org/10.1182/blood.V128.22.947.947

Published: 2016

Journal Articles

Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis

Mohamad Jawhar, MD, Nicole Naumann, Sebastian Kluger, Juliana Schwaab, MD, Georgia Metzgeroth, MD, Erica K. Evans, PhD, Alexandra Gardino, PhD, Christoph Lengauer, PhD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Alice Fabarius, PhD, Andreas Reiter, MD

Blood (2016) 128 (22): 1964.

https://doi.org/10.1182/blood.V128.22.1964.1964

Published: 2016

Journal Articles

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Sebastian Kreil, MD PhD, Lionel Adès, MD PhD, Martin Bommer, MD, Frank Stegelmann, MD, Mark E Ethell, MBBChir, MA, FRCP, FRCPath, Anna Lubking, MD, Peter Martin, MD, Ekkehard Eigendorff, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Andreas Hochhaus, MD, Andreas Reiter, MD

Blood (2015) 126 (23): 2812.

https://doi.org/10.1182/blood.V126.23.2812.2812

Published: 2015

Journal Articles

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas C.P. Cross, PhD, Andrzej Hellman, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Medina Almeida, Arpad Illes, MD PhD, Cristalina Fernandez, Luca Dezzani, Angela Pellegrino, Chiara Costantini, Claudia Walasek, Giuseppe Saglio, Juan Luis Steegmann, MD, Michele Baccarani

Blood (2015) 126 (23): 4040.

https://doi.org/10.1182/blood.V126.23.4040.4040

Published: 2015

Journal Articles

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 4054.

https://doi.org/10.1182/blood.V126.23.4054.4054

Published: 2015

Journal Articles

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 479.

https://doi.org/10.1182/blood.V126.23.479.479

Published: 2015

Journal Articles

Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V + Advanced Systemic Mastocytosis

Mohamad Jawhar, Juliana Schwaab, MD, Susanne Schnittger, PhD, Manja Meggendorfer, PhD, Karl Sotlar, MD, Hans-Peter Horny, MD, Georgia Metzgeroth, MD, Sebastian Kluger, Nicole Naumann, Claudia Haferlach, MD, Torsten Haferlach, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Alice Charlotte Fabarius, PhD, Nicholas C.P. Cross, PhD, Andreas Reiter, MD

Blood (2015) 126 (23): 349.

https://doi.org/10.1182/blood.V126.23.349.349

Published: 2015

Journal Articles

Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event

Mohamad Jawhar, MD, Juliana Schwaab, MD, Susanne Schnittger, PhD, Karl Sotlar, MD, Hans Peter Horny, MD, Georgia Metzgeroth, Sven Schneider, MD, Nadine Müller, Nicole Naumann, Christoph Walz, MD, Torsten Haferlach, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Alice Fabarius, PhD, Andreas Reiter, MD

Blood (2014) 124 (21): 3216.

https://doi.org/10.1182/blood.V124.21.3216.3216

Published: 2014

Journal Articles

Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia

Sara Redaelli, PhD, Rocco Piazza, MD PhD, Alessandra Pirola, M.Sc., Vera Magistroni, PhD, Susanne Schnittger, PhD, Manja Meggendorfer, PhD, Nicholas C.P. Cross, PhD, Delphine Rea, MD PhD, Carlo Gambacorti-Passerini, MD

Blood (2014) 124 (21): 3576.

https://doi.org/10.1182/blood.V124.21.3576.3576

Published: 2014

Journal Articles

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Jyoti Nangalia, MBBChir FRCPath, Charles Massie, PhD, E Joanna Baxter, PhD, Francesca L Nice, MRes, Gunes Gundem, PhD, David Wedge, PhD, Edward Avezov, PhD, Juan Li, PhD, Karoline Kollmann, PhD, David G. Kent, PhD, Athar Aziz, PhD, Anna L Godfrey, BMBCh FRCPath, Jonathan Hinton, MSc, Inigo Martincorena, PhD, Peter Van Loo, PhD, Amy V Jones, PhD, Paola Guglielmelli, PhD MD, Patrick Tarpey, PhD, Heather P Harding, PhD, John D Fitzpatrick, BA, Calum T Goudie, BA, Christina A Ortmann, MD, Stephen J Loughran, PhD, Keiran Raine, MSc, David Jones, MSc, Adam Butler, MSc, Jon W Teague, MSc, Sarah O'Meara, Stuart McLaren, Michele Bianchi, Yvonne Silber, MSc, Danai Dimitropolou, BSc, David Bloxham, MSc FRCPath, Laura J Mudie, BSc, Mark Maddison, BSc, Ben Robinson, BSc, Clodagh Keohane, MD, Cathy MacLean, MSc, Kate Hill, BM BS, Kim H. Orchard, MBBS, PhD, FRCP, FRCPath, Sudhir Tauro, PhD, Ming-Qing Du, MB, PhD, Mel Greaves, PhD, FRS, David Bowen, MD, PhD, Brian Huntly, MBChB FRCPath PhD, Claire N Harrison, DM, FRCP, FRCPath, Nicholas C.P. Cross, PhD, FRCPath, David Ron, MD, Alessandro M Vannucchi, MD, Elli Papaemmanuil, PhD, Peter J. Campbell, PhD, Anthony R Green, FRCPath FMedSci

Blood (2013) 122 (21): LBA-2.

https://doi.org/10.1182/blood.V122.21.LBA-2.LBA-2

Published: 2013

Journal Articles

Latent Myeloproliferative Neoplasm May Underlie Retinal Vein Occlusion In Older Patients

Katerina Zoi, PhD, Christine Zoi, Andreas Giannopoulos, MSc, Argyri Gialeraki, PhD, Kassiani Giannaki, MD, PhD, Niki Rougkala, Panagiotis Theodosiadis, MD, John Vergados, MD, Dimitris Loukopoulos, Nicholas C.P. Cross, PhD, FRCPath, Marianna Politou

Blood (2013) 122 (21): 5242.

https://doi.org/10.1182/blood.V122.21.5242.5242

Published: 2013

Journal Articles

SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia

Rocco Piazza, MD, PhD, Sara Redaelli, PhD, Simona Valletta, Alessandra Pirola, M.Sc., Roberta Spinelli, M.Sc., Vera Magistroni, PhD, Dong-Wook Kim, MD, PhD, Nicholas C.P. Cross, PhD, Carlo Gambacorti-Passerini, MD

Blood (2013) 122 (21): 2598.

https://doi.org/10.1182/blood.V122.21.2598.2598

Published: 2013

Journal Articles

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Blood (2013) 122 (21): 4030.

https://doi.org/10.1182/blood.V122.21.4030.4030

Published: 2013

NARROW

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience

Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis

Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis

Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis

Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V + Advanced Systemic Mastocytosis

Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event

Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Latent Myeloproliferative Neoplasm May Underlie Retinal Vein Occlusion In Older Patients

SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only